Stivarga is the brand name form of regorafenib, a type of oral cancer medication. Stivarga works by interfering with the growth and spread of cancer cells in the body. Stivarga is usually given after other cancer drugs have failed. Stivarga was developed by a German company Bayer and has been approved for use in type-targeted therapy. Stivarga works by inhibiting growth in various types of kinase proteins which inhibit growth of cancerous tumors.